Trial Profile
Effects of Biectegravir-Emtricitabine-Tenofovir Alafenamide on Coronary Flow Reserve in Stable HIV Patients (B/F/TAF-CFR) - Pilot Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications Coronary artery disease; HIV infections
- Focus Pharmacodynamics
- Acronyms BETTER
- 24 Jan 2023 Status changed from active, no longer recruiting to completed.
- 07 Jun 2021 Status changed from recruiting to active, no longer recruiting.
- 05 Jan 2021 Planned End Date changed from 30 Nov 2020 to 30 Nov 2021.